Open Eye Corneal Swelling With Daily Disposable Contact Lenses and no Lens Wear

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Vision Care, Inc.
ClinicalTrials.gov Identifier:
NCT01765972
First received: January 8, 2013
Last updated: June 10, 2016
Last verified: June 2016
  Purpose
The primary purpose of this clinical trial is to evaluate the eye's response to three test soft contact lenses as well as no lens wear, with respect to Corneal Staining.

Condition Intervention
Corneal Swelling
Device: etafilcon A with Lacreon
Device: etafilcon A with Lacreon with print
Device: etafilcon A with print
Device: Spectacles (habitual)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Johnson & Johnson Vision Care, Inc.:

Primary Outcome Measures:
  • Corneal Swelling [ Time Frame: 8 hours post fit ] [ Designated as safety issue: No ]
    Central corneal thickness was measured at baseline and 8-hour post fit with a modified optical pachometer on a Zeiss biomicroscope, interfaced to a PC. The pachometry measurement included seven readings; the computer is programmed to remove the high and low readings and to calculate the average of the remaining five readings. Only a single central corneal thickness measurement, the average of the 5 readings, was recorded by the investigator in the eCRF. The average percent change from baseline of corneal swelling was reported and was calculated as: ((Post fit - Baseline)/ Baseline) X 100.


Enrollment: 39
Study Start Date: December 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Test 1/Spectacles/Test 2/Test 3
Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 1 (etafilcon A with Lacreon), spectacles, TEST 2 (etafilcon A with Lacreon with print) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
Device: etafilcon A with Lacreon
contact lens with Lacreon
Other Name: Test 1
Device: etafilcon A with Lacreon with print
contact lens with Lacreon and cosmetic print
Other Name: Test 2
Device: etafilcon A with print
contact lens with print
Other Name: Test 3
Device: Spectacles (habitual)
Spectacles
Test 2/Test 3/ Spectacles/Test 1
Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 2 (etafilcon A with Lacreon with print), TEST 3 (etafilcon A with print), spectacles and TEST 1 (etafilcon A with Lacreon) in both eyes for 8 +/-1 hours.
Device: etafilcon A with Lacreon
contact lens with Lacreon
Other Name: Test 1
Device: etafilcon A with Lacreon with print
contact lens with Lacreon and cosmetic print
Other Name: Test 2
Device: etafilcon A with print
contact lens with print
Other Name: Test 3
Device: Spectacles (habitual)
Spectacles
Test 3/Test 1/ Test 2/ Spectacles
Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 3 (etafilcon A with print), TEST 1 (etafilcon A with Lacreon), TEST 2 (etafilcon A with Lacreon with print) and spectacles in both eyes for 8 +/-1 hours.
Device: etafilcon A with Lacreon
contact lens with Lacreon
Other Name: Test 1
Device: etafilcon A with Lacreon with print
contact lens with Lacreon and cosmetic print
Other Name: Test 2
Device: etafilcon A with print
contact lens with print
Other Name: Test 3
Device: Spectacles (habitual)
Spectacles
Spectacles/Test 2/Test 1/Test 3
Subjects assigned randomly to this arm will wear the study lenses sequentially as spectacles, TEST 2 (etafilcon A with Lacreon with print), TEST 1 (etafilcon A with Lacreon) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
Device: etafilcon A with Lacreon
contact lens with Lacreon
Other Name: Test 1
Device: etafilcon A with Lacreon with print
contact lens with Lacreon and cosmetic print
Other Name: Test 2
Device: etafilcon A with print
contact lens with print
Other Name: Test 3
Device: Spectacles (habitual)
Spectacles

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  2. The subject must appear able and willing to adhere to the instructions set forth in the clinical protocol.
  3. The subject must be between 18 and 45 years of age.
  4. The subject must be an adapted soft contact lens wearer in both eyes.
  5. The subject must be of East or Southeast Asian descent, e.g. ethnic Chinese, Japanese, Korean, Malay, Vietnamese, Indonesian, Filipino, etc. (it is preferred but not required that both the subject's biological parents are East or Southeast Asian ethnicity, by self report).
  6. The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 D in each eye.
  7. The subject's refractive cylinder must be no more than 1.00D in each eye.
  8. The subject must have best corrected visual acuity of +0.14 logMAR (equivalent to 20/25-2) or better in each eye.
  9. Subjects must own a wearable pair of spectacles and wear them on the day of the initial visit, during the washout before each phase and during the no lens wear phase.
  10. The subject must have normal eyes (i.e., no ocular medications or infections of any type).

Exclusion Criteria:

  1. Are currently pregnant or lactating by self report (subjects who become pregnant during the study will be discontinued).
  2. Have any ocular or systemic allergies or diseases that may interfere with contact lens wear.
  3. Have any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but may not be limited to, diabetes. hyperthyroidism, recurrent herpes simplex/zoster, Sjogren's syndromes, xerophthalmia, acne rosacea, Stevens-Johnson syndromes, HIV/AIDS, hepatitis, and tuberculosis.
  4. Use of any topical medications such aas eye drops or ointments.
  5. Have entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosion, or aphakia.
  6. Had any previous, or planned ocular or intraocular surgery (e.g. cataract surgery, radial keratotomy, PRK, LASIK, etc.).
  7. Have any grade 2.0 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the Efron classification scale or any other ocular abnormality that may contraindicate contact lens wear.
  8. Have any known hypersensitivity or allergic reaction to one of the study products.
  9. Have any ocular infection.
  10. Have any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  11. Have participated in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
  12. Have any infectious disease (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV by self report).
  13. Currently wear their contact lenses on an extended wear basis.
  14. Are an employee of the investigational clinic (e.g. Investigator, Coordinator, Technician)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01765972

Locations
Canada, Ontario
Waterloo, Ontario, Canada
Sponsors and Collaborators
Johnson & Johnson Vision Care, Inc.
  More Information

Responsible Party: Johnson & Johnson Vision Care, Inc.
ClinicalTrials.gov Identifier: NCT01765972     History of Changes
Other Study ID Numbers: CR-5252 
Study First Received: January 8, 2013
Results First Received: June 10, 2016
Last Updated: June 10, 2016
Health Authority: Canada: Health Canada

ClinicalTrials.gov processed this record on July 21, 2016